West Michigan Catholics watch as pope remains hospitalized
'There's of course a certain sadness,' Rev. Robert Sirico, pastor emeritus of in Grand Rapids, said. 'You have a father in his final days, probably. So there is concern.'
The Diocese of Grand Rapids and are turning to prayer as they consider daily updates on the pope's battle with double pneumonia.
Pope Francis shows slight improvement as he battles pneumonia
Sirico recently helped the city's youngest parishioners begin to sort through their feelings.
'(Grand Rapids Diocese) Bishop (David) Walkowiak has asked all Catholic parishes to be in prayer for the Holy Father. There's a lot of rosaries that have been led,' Sirico told News 8. 'I just came from Mass with the children. I talked to them about losing a parent and needing to be close to him in prayer. So the children are praying for him.'
For some, the distinctive style and politics of Pope Francis make dealing with his potential passing complicated.
'I think his legacy is yet to be determined,' Sirico said. 'It is true that this is a very distinctive pontificate. What he did in any formal statement having to do with doctrine or hot-button issues was always to affirm the perennial teaching of the Catholic Church, but what he attempted to do was reach out with great compassion to people who would feel alienated by that message. In doing so, I think Francis emulated the example of Christ. It's no secret a lot of people disagreed with a lot (he) said or did, but even then, there is an affection for the role he has played and the good he has attempted to do.'
'Old and new coming together': Former home of Dominican Sisters becomes senior housing
Last year, Pope Francis made changes to the traditional burial rites for a pope. He moved to eliminate the requirement for three coffins of cypress, lead and oak as well as the elevated bier for public viewing. He instead elected to be viewed in a simple, zinc-lined wooden coffin at ground level. He will also be buried at the Basilica of Santa Maria Maggiore in Rome. He said the changes are to reflect and emphasize the Roman pontiff's funeral is that of a shepherd and disciple of Christ, and not of a powerful man of this world.
None of those proceedings will begin, though, until the mourning bell at Saint Peter's Basilica is rung. For now, Catholics continue to pray.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
5 days ago
- Boston Globe
Vatican strikes a solar deal that aims to make it the world's first carbon-neutral state
Over the years as the area became more developed, residents began complaining of health problems, including instances of childhood leukemia which they blamed on the electromagnetic waves generated by the towers. The Vatican denied there was any causal link but cut back the transmissions. Advertisement Pope Francis last year tasked the Vatican to study developing the area into a vast solar farm, hoping to put into practice his preaching about the need to transition away from fossil fuels and find clean, carbon-neutral energy sources. Pope Leo XIV visited the site in June and affirmed that he intended to see Francis' vision through. Leo has strongly taken up Francis' ecological mantle, recently using a new set of prayers and readings inspired by Pope Francis' environmental legacy. Advertisement The agreement signed Thursday stipulates that the development of the site will preserve the agricultural use of the land and minimize the environmental impact on the territory, according to a Vatican statement. Vatican officials have estimated it will cost under 100 million euros to develop the solar farm, and that once approved by Italy, the contracts to do the work can be put up for bids. In the 1990s at the height of the controversy, residents sued Vatican Radio officials, claiming the emissions exceeded the Italian legal limit, but the court cleared the transmitter. In 2012, the Vatican announced it was cutting in half the hours of transmission from the site, not because of health concerns but because of cost-saving technological advances in internet broadcasting. Associated Press religion coverage receives support through the AP's collaboration with The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content.
Yahoo
25-07-2025
- Yahoo
Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)
In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to overlook some of the most transformative developments in the life sciences. Cathie Wood, CEO of ARK Invest and known for her bold bets on disruptive innovation, has her sights set on Illumina (ILMN), a company that connects science and technology. On July 22, Wood's ARK's Genomic Revolution ETF (ARKG) bought 31,265 shares of Illumina, amounting to nearly $2.98 million, bringing the total investment in the company to $32 million. It is the ETF's 15th largest holding, comprising 2.8% of the overall portfolio. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Let's find out if investors should follow Wood's lead and buy Illumina stock here. A High-Conviction Bet on the Future of Medicine Valued at $16.6 billion, Illumina is a biotechnology company that specializes in genome sequencing, or the process of reading and analyzing DNA. It manufactures machines (sequencers), software, and chemical kits that are used to decode the genetic material (DNA) of humans, animals, plants, and bacteria. Illumina's technology is used in hospitals and clinics, by cancer researchers, pharmaceutical companies, agricultural scientists, academics, and research institutions, among others. Some of its products include the NovaSeq X Series, iScan System, iSeq 100 System, Illumina DNA Prep, Illumina Stranded mRNA Prep, and many others. Illumina's stock price has dropped significantly since its 2021 highs, falling from above $500 to around the $100-$120 range by mid-2025. Much of this decline can be attributed to a series of self-inflicted wounds, most notably its controversial acquisition of cancer detection company Grail. However, with the Grail divestment in 2024 and a new CEO, Jacob Thaysen, in charge, Illumina appears to be refocusing on its core business of making genome sequencing cheaper, faster, and more accessible. Why the Timing Matters Now Wood is known for buying when volatility is high, particularly when she believes the market has overcorrected due to near-term concerns. Following the Grail divestment, leadership change, and a multi-quarter slump in revenue growth, investor sentiment is bearish on Illumina stock, explaining the nearly 20% drop year-to-date. However, Wood saw this as an opportunity to stock up on this rising genomic star. Illumina's financial performance appears to be stabilizing. For a growth investor like Wood, who prefers to overlook short-term earnings volatility in favor of long-term potential, these improvements are a welcome sign that the company is on the right track. In the first quarter, while revenue growth dipped slightly by 1.4%, the company improved its margins and reduced unnecessary expenses. Illumina exceeded revenue expectations and reaffirmed full-year guidance. Adjusted gross margins increased to 67.4% as a result of improved manufacturing efficiency and lower R&D costs. Adjusted earnings per share fell to $0.97 from $0.98 in the prior year's quarter. Remaining performance obligations (RPO) totaled $891 million, of which Illumina expects to generate 83% in revenue over the next year. With a reasonable debt-equity ratio of 0.63x, Illumina's balance sheet is stable. The company also generated a positive free cash flow of $208 million during the quarter. Illumina will report its second-quarter earnings on July 31. Analysts expect revenue of $1.05 billion on earnings per share of $1.01. Analysts predict a 3% drop in revenue for the full year but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026. Another factor that may have influenced ARK's decision to increase its stake in Illumina is valuation. The stock is currently trading at 22 times forward earnings for 2026 and three times forward sales. Illumina has the world's largest genomics dataset, giving the company a competitive advantage. Many of Illumina's future revenue streams, including large-scale population sequencing contracts and new clinical applications in oncology and rare diseases, are not fully priced into current projections. This reasonable valuation represents a buying opportunity for a growth stock with excellent long-term prospects. What Is Wall Street Saying About Illumina Stock? Overall, the consensus on Illumina stock is a 'Moderate Buy.' Of the 22 analysts covering the stock, nine recommend a 'Strong Buy,' one suggests a 'Moderate Buy,' nine rate it a 'Hold,' one says it is a 'Moderate Sell,' and two have given it a 'Strong Sell' rating. The stock is trading close to its average target price of $106.83. However, the high price estimate of $185 suggests a rally of over 76.8% from current levels. The Key Takeaway Wood's stake in Illumina is a calculated investment based on extensive research, long-term vision, and a firm belief in the power of genomics to transform healthcare. Now, with a lower cost structure, a clear path back to profit growth, and exciting new products on the market, Illumina is poised for a turnaround. For investors with patience and a long horizon, Illumina stock represents a one-of-a-kind opportunity to invest in genomic infrastructure. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Chicago Tribune
23-07-2025
- Chicago Tribune
8 children taken to hospitals after seizure-like symptoms at Harvard Square church concert
CAMBRIDGE, Mass. — Eight children at a church near Harvard University where a French youth choir was holding a concert suffered seizure-like symptoms and were taken to hospitals, officials said. The symptoms were not life-threatening, the Cambridge Fire Department said in a news release. About 70 other people in attendance at the concert Tuesday evening at St. Paul's Parish in Harvard Square were not affected. Crews first received a call about a child suffering from a seizure. When firefighters arrived, the child was sitting outside of the church but was not actively having a seizure, Fire Chief Thomas Cahill said. 'That quickly escalated into seven other people having seizure-like symptoms,' Cahill told WCVB-TV. The department's hazmat team 'completed a thorough survey of the St. Paul buildings utilizing several air sampling meters to ensure that no hazardous conditions were present,' the news release said. 'Results were negative and the buildings were ventilated.' St. Paul's Facebook Page said a French youth choir, the Chœur d'Enfants d'Île-de-France, was offering a free concert at the church on Tuesday night as part of its 2025 U.S. tour. 'Founded in 1970, the youth choir has travelled extensively and performed with some of the world's top conductors and soloists,' St. Paul's said. 'The concert will feature and exciting mix of sacred and secular repertoire, as well as popular French songs.' Messages seeking comment were emailed to St. Paul's and to the Harvard Catholic Center, the Catholic chaplaincy for Harvard University students and other academic institutions in the area.
